Health Trials

SDH Gene Mutation

2

Review clinical trials related to SDH Gene Mutation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

PH 2 Pemigatinib in SDH-deficient GIST

The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. The name of the study drug involved in this study is: • Pemigatinib (INCB054828)

Participants needed: 24
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: May 22, 2026Locations: 1
Eligibility criteria

Participant must have histologically confirmed SDH-deficient GIST. Participants... [+23]

Participants who are receiving any other investigational agents. [+16]

Read more
Status: Not yet recruiting

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers

The primary objective of the PGL.EXPO-2 study is to test the hypothesis that exposure (occupational, environmental and/or domestic) to succinate dehydrogenase inhibitors (SDHi) could contribute to tumor emergence in subjects carrying a germline mutation in one of the SDHx genes.The primary endpoint will be the proportion of subjects (cases or controls) exposed to SDHi and the association with paraganglioma risk. In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study

Participants needed: 1,300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Assistance Publique - Hôpitaux de ParisUpdated: May 10, 2024Locations: 20
Eligibility criteria

Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor [+1]

Incapacity to exercise free and informed consent for the study [+1]

Read more